The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\<10 mIU/mL) need to take.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 36
Healthy Volunteers: t
View:

• The actual age at the time of admission was higher than 20 years old and birth year after 1987

• Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period.

• Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline

• Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire

• Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process

• In good health

Locations
Other Locations
Taiwan
Family Medicine, NTUH
RECRUITING
Taipei
Contact Information
Primary
CHYI-FENG JAN, MD, PHD
jcf036@gmail.com
+886-2-23123456
Time Frame
Start Date: 2021-08-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 240
Treatments
Experimental: Low titer with two doses of HB Vaccines
anti-HBs titer 2.5-10 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
Active_comparator: Low titer with one dose of HB Vaccine
anti-HBs titer 2.5-10 mIU/mL with one dose of HB Vaccine at Day 0
Active_comparator: Extremely low titer with two doses of HB Vaccines
anti-HBs titer lower than 2.5 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
Active_comparator: Extremely low titer with one dose of HB Vaccine
anti-HBs titer lower than 2.5 mIU/mL with one dose of HB Vaccine at Day 0
Related Therapeutic Areas
Sponsors
Collaborators: Ministry of Science and Technology, Taiwan, Academia Sinica, Taiwan
Leads: National Taiwan University Hospital

This content was sourced from clinicaltrials.gov